Participated · Series B · Aug 2026

Mironid develops first-in-class small-molecule LoAc® drug candidates that directly target abnormally high kidney cAMP levels that drive cyst formation in ADPKD. Its lead programmes are focused on treating Autosomal Dominant Polycystic Kidney Disease, a hereditary disorder affecting over 12 million people worldwide with about 50% of patients developing kidney failure by age 60. The company was founded through collaboration between the University of Strathclyde and Heriot-Watt University and is led by CEO Neil Wilkie. Mironid has progressed a series of drug-development programmes targeting specific enzymes to generate differentiated therapies for diseases with high unmet need. The recently closed £34m Series B, which includes an £8.4m equity investment from SNIB and participation from Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures and the University of Strathclyde, will fund clinical development and advancement of its lead candidate.

Led · Series A · Dec 2025

TargED Biopharmaceuticals B.V., founded in 2020 as a spin-out from University Medical Center Utrecht, is focused on TGD001, an antibody-enzyme fusion protein that binds von Willebrand factor (VWF) and degrades both VWF and fibrin to dissolve clots. The therapy has completed a Phase 1 first-in-human study that showed a favorable safety profile with no spontaneous bleeding events and potent thrombolytic activity. With its latest funding, the company will initiate two Phase 1/2 clinical studies targeting acute ischemic stroke and thrombotic microangiopathies, expanding trial sites across Europe and the U.S. and aiming for first data in 2026. Unlike approved thrombolytics that target a single pathway, TGD001 leverages the ubiquitous presence of VWF to enable broad clot dissolution. TargED has raised over €60 million in Series A financing to date and also received a blended-finance grant from the European Innovation Council Accelerator in 2025. The fresh capital strengthens its balance sheet and accelerates clinical development toward demonstrating proof-of-concept in multiple life-threatening indications.

Participated · Series B · May 2025

Azafaros is a clinical-stage company developing disease-modifying therapeutics for rare lysosomal storage disorders, leveraging science from Leiden University and Amsterdam UMC. Its lead asset, nizubaglustat, is an orally available, brain-penetrant small molecule with a dual mode of action targeting CNS-involved GM1/GM2 gangliosidoses and Niemann-Pick disease Type C (NPC). Nizubaglustat has received multiple regulatory designations, including Orphan Drug Designations in the US and EU, Rare Pediatric Disease Designations, Fast Track status in the US, and an Innovation Passport from the UK MHRA. The company plans to initiate two Phase 3 pivotal studies for nizubaglustat (NPC and GM1/GM2) later this year and intends to expand its pipeline into additional indications. Azafaros was founded in 2018 and is led by an experienced team focused on rapid development and commercialization for rare genetic diseases. The recently completed oversubscribed financing strengthens its financial position to execute these clinical plans. Azafaros develops orally available small‑molecule therapeutics (azasugars) aimed at disease modification in rare genetic metabolic disorders, initially targeting lysosomal storage diseases. The company holds an exclusive license from Leiden University and Amsterdam UMC to a library of novel patented compounds discovered by researchers including Professors Hans Aerts, Hermen Overkleeft and Stan van Boeckel. Its proprietary lead compound, AZ‑3102, is an oral azasugar that interferes with glycolipid metabolism and exerts a dual mode of action on key disease pathways. Azafaros says it is advancing the lead program toward first‑in‑man studies while expanding its discovery efforts to broaden the pipeline into other rare metabolic diseases. The Series A financing provides capital to build the organization and expand the executive team to support these development plans. No operating revenues or user metrics are disclosed in the article.

Participated · Seed · Apr 2025

Avidicure is pioneering an entirely new multifunctional antibody modality, branded AVC-Boosters, with broad applicability in oncology. The AVC-Boosters are dual agonistic, multifunctional and avidity-engineered antibodies designed to elicit orchestrated innate and adaptive immune responses as targeted cancer monotherapies. The company leverages a fully owned proprietary platform combining decades of antibody engineering, in silico protein design capabilities, and immunology expertise. Through AVC-Booster plug-and-play functionality, multiple products can be developed from the platform. Avidicure's lead product, AVC-S-101, is a TROP2-targeting booster being developed for non-small cell lung cancer and multiple other indications. The founding management team is led by CEO Arthur Lahr, with Dirk De Naeyer (COO), Robert Friesen (CSO) and Govert Schouten (CBO). Avidicure raised $50m in seed financing to advance its programs; no operating metrics were reported in the article.

Participated · Series A · Jan 2025

RhyGaze is a biotechnology company based in Basel, Switzerland and Philadelphia, Pa., focused on developing gene therapies for retinal diseases that cause blindness. Its lead clinical candidate is a novel gene therapy for optogenetic vision restoration. The company was founded on intellectual property exclusively licensed from the Institute of Molecular and Clinical Ophthalmology Basel (IOB); IOB scientists Botond Roska, Bence György and Charles Gubser are scientific founders. RhyGaze plans to use funding to complete formal pharmacology and toxicology testing, run a non‑interventional observational study to assess potential clinical endpoints, and initiate a first‑in‑human clinical trial to evaluate safety, tolerability and potential efficacy. The company is led by CEO Dr. Katherine High and aims to translate preclinical data from IOB into clinical outcomes. Financially, RhyGaze recently raised significant Series A capital to advance its lead program, supplementing an earlier seed investment from its founding backers.